###begin article-title 0
The role of T cell interleukin-17 in conducting destructive arthritis: lessons from animal models
###end article-title 0
###begin p 1
###xml 664 673 652 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 677 684 665 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 801 809 789 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 849 857 837 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 184 192 <span type="species:ncbi:9606">patients</span>
Interleukin-17 (IL-17) is a T cell cytokine spontaneously produced by cultures of rheumatoid arthritis (RA) synovial membranes. High levels have been detected in the synovial fluid of patients with RA. The trigger for IL-17 is not fully identified; however, IL-23 promotes the production of IL-17 and a strong correlation between IL-15 and IL-17 levels in synovial fluid has been observed. IL-17 is a potent inducer of various cytokines such as tumor necrosis factor (TNF)-alpha, IL-1, and receptor activator of NF-kappaB ligand (RANKL). Additive or even synergistic effects with IL-1 and TNF-alpha in inducing cytokine expression and joint damage have been shown in vitro and in vivo. This review describes the role of IL-17 in the pathogenesis of destructive arthritis with a major focus on studies in vivo in arthritis models. From these studies in vivo it can be concluded that IL-17 becomes significant when T cells are a major element of the arthritis process. Moreover, IL-17 has the capacity to induce joint destruction in an IL-1-independent manner and can bypass TNF-dependent arthritis. Anti-IL-17 cytokine therapy is of interest as an additional new anti-rheumatic strategy for RA, in particular in situations in which elevated IL-17 might attenuate the response to anti-TNF/anti-IL-1 therapy.
###end p 1
###begin title 2
Interleukin-17 and family members
###end title 2
###begin p 3
###xml 167 168 160 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 171 172 164 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 175 177 168 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 189 190 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 191 192 184 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 321 322 314 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 405 406 398 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 498 499 491 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 500 501 493 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 502 503 495 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 700 701 693 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 702 703 695 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 884 885 877 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 888 889 881 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 125 130 <span type="species:ncbi:9606">human</span>
###xml 149 154 <span type="species:ncbi:10090">mouse</span>
###xml 275 278 <span type="species:ncbi:10116">rat</span>
###xml 328 333 <span type="species:ncbi:10090">mouse</span>
###xml 427 432 <span type="species:ncbi:9606">human</span>
###xml 448 453 <span type="species:ncbi:10090">mouse</span>
###xml 506 511 <span type="species:ncbi:9606">Human</span>
###xml 558 563 <span type="species:ncbi:10090">mouse</span>
###xml 842 847 <span type="species:ncbi:9606">human</span>
Interleukin-17 (IL-17) is a 17 kDa protein that is secreted as a dimer by a restricted set of cells, predominantly activated human memory T cells or mouse alphabetaTCR+CD4-CD8- thymocytes [1-3]. Rouvier and colleagues have cloned cytotoxic T lymphocyte-associated antigen-8 (rat IL-17) from a T cell subtraction library [4] and mouse IL-17 was cloned from a thymus-derived, activated T cell cDNA library [3]. Subsequently, the human counterpart of mouse IL-17 was cloned by two independent groups [1,2,5]. Human IL-17 has 25% amino acid sequence homology to mouse IL-17, as well as 72% homology to an open-reading frame from the T lymphotropic herpes virus saimiri (HVS13) and 63% homology to CTLA8 [2,4]. In addition to IL-17 (IL-17A) another five members of the IL-17 family have been discovered (IL-17B-F) by large-scale sequencing of the human and other vertebrate genomes (Table 1) [6].
###end p 3
###begin p 4
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 211 212 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
The different IL-17 family members seem to have very distinct expression patterns, suggesting distinct biological roles. IL-17B is moderately expressed in several peripheral tissues as well as immune tissues [7,8], and IL-17E is expressed in various peripheral tissues [9]. Interestingly, IL-17F has biological functions similar to those of IL-17(A) and is also produced by activated monocytes [10,11]. This indicates that the IL-17 family might contribute to the pathology of rheumatoid arthritis (RA) and other inflammatory diseases not only through activated T cells but also through activated monocytes/macrophages. Further work will be required to determine the precise mechanism of action of IL-17 and its family members such as IL-17F, IL-17B, and IL-17E in the development of chronic synovitis and tissue destruction during arthritis, especially in relation to other known key cytokines (IL-1, tumor necrosis factor [TNF], and receptor activator of NF-kappaB ligand [RANKL]).
###end p 4
###begin title 5
IL-17 signaling
###end title 5
###begin p 6
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 741 743 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 744 746 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 802 804 798 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 824 826 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 910 911 906 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 942 944 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1018 1020 1014 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1029 1030 1025 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
In contrast to the restricted expression of IL-17, the IL-17 receptor (IL-17R) is ubiquitously expressed in virtually all cells and tissues. It is a type I transmembrane protein that has no sequence similarity to any other known cytokine receptor [5]. The exact mechanisms of IL-17 signaling are not fully elucidated. Binding of IL-17 to its unique receptor results in activation of the adapter molecule TNF-receptor-associated factor 6 (TRAF6), which is required for IL-17 signaling [12]. IL-17 shares transcriptional pathways with IL-1 and TNF. It can activate NF-kappaB and all three classes of mitogen-activated protein (MAP) kinases including extracellular signal-related kinase (ERK)1 and ERK2, c-Jun N-terminal kinase (JNK), and p38 [13-15]. These pathways have been identified in synoviocytes [16] and chondrocytes [14]. Four other receptors for the IL-17 family have been identified so far: IL-17RH1 [8] and IL-17RL (receptor-like) [17], IL-17RD, and IL-17RE, which share partial sequence homology to IL-17R [18] (Table 1). The expression pattern of these new receptors seems to be more cell/tissue-specific than that of the IL-17R, and the ligand specificities of many of these receptors have not been established.
###end p 6
###begin title 7
Regulation of IL-17
###end title 7
###begin p 8
###xml 204 206 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 534 536 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 641 643 637 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 644 646 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 790 792 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 872 874 868 870 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 883 885 879 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 886 888 882 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1062 1064 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 178 184 <span type="species:ncbi:10090">murine</span>
###xml 189 194 <span type="species:ncbi:9606">human</span>
###xml 230 235 <span type="species:ncbi:9606">human</span>
The physiological stimulus for the induction of IL-17 expression has not been fully identified. Microbial stimuli induced the expression of IL-17 together with TNF-alpha in both murine and human T cells [19]. Cell-cell contact of human T cells with fibroblasts resulted in increased mRNA expression of IL-17 and IL-17R. Supernatants obtained from cell-cell contact-stimulated peripheral blood lymphocytes enhance the production of IL-6 and IL-8 by fibroblast-like synoviocytes, an effect that was blocked by antibodies against IL-17 [20]. Furthermore, IL-15 produced by synoviocytes is considered to be a potent inducer of IL-17 production [21,22]. Moreover, IL-23 produced by activated DCs and macrophages acts on memory T cells, promoting the production of IL-17 (both IL-17 and IL-17F) [23]. In addition, a direct role was suggested for IL-23 in IL-17 production by CD8+ T cells [23,24]. IL-23 affects memory T cell and inflammatory macrophage function, and IL-23 (but not IL-12) is a critical factor in autoimmune inflammation to the central nervous system [25].
###end p 8
###begin p 9
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 333 335 333 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 517 519 513 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 676 678 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 761 763 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 764 766 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1000 1002 989 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1003 1005 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
###xml 478 482 <span type="species:ncbi:10090">mice</span>
###xml 670 674 <span type="species:ncbi:10090">mice</span>
###xml 710 714 <span type="species:ncbi:10090">mice</span>
###xml 740 744 <span type="species:ncbi:10090">mice</span>
Further support for IL-23 as an important trigger for IL-17 was obtained from studies with IL-23-specific knockout mice [26,27]. Specific absence of IL-23 completely prevented collagen-induced arthritis (CIA), whereas loss of IL-12 exacerbates CIA [26]. Interestingly, resistance was correlated with an absence of IL-17-producing CD4+ T cells despite normal induction of collagen-specific, interferon-gamma-producing T helper 1 cells. In contrast, IL-12-deficient p35-deficient mice developed more IL-17-producing CD4+ T cells, as well as an elevated expression of proinflammatory cytokines (such as TNF-alpha, IL-1beta, IL-6, and IL-17) in affected tissues of diseased mice [26]. Importantly, IL-23-deficient mice resemble IL-17-deficient mice phenotypically [27,28]. These studies indicate the existence of an IL-23/IL-17 axis of communication between the innate and adaptive parts of the immune system that might be an interesting target for the immunotherapy of inflammatory autoimmune diseases [26,27].
###end p 9
###begin title 10
Role of IL-17 in the pathogenesis of RA
###end title 10
###begin p 11
RA is a chronic systemic disorder that is characterized by autoimmunity, infiltration of joint synovium by activated inflammatory cells, synovial hyperplasia, neoangiogenesis and progressive destruction of cartilage and bone. RA is considered to be a systemic Th1-associated inflammatory joint disease, and T cells comprise a large proportion of the inflammatory cells invading the synovial tissue. T cell activation and migration into the synovium occur as an early consequence of disease, and these cells adopt a pro-inflammatory phenotype. Considerable evidence now supports a role for T cells in the initiation and perpetuation of chronic inflammation prevalent in RA. Although T cells represent a large proportion of the inflammatory cells during inflammation, T cell-derived cytokines are much less abundant. However, because the vast majority of these are memory T cells, IL-17 is upregulated in early disease.
###end p 11
###begin p 12
###xml 48 57 48 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 794 796 794 796 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 860 862 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 981 983 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1074 1076 1070 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1245 1246 1237 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1247 1248 1239 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1374 1376 1366 1368 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1377 1378 1369 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 441 449 <span type="species:ncbi:9606">patients</span>
###xml 937 942 <span type="species:ncbi:9606">human</span>
###xml 989 993 <span type="species:ncbi:10090">mice</span>
###xml 1276 1281 <span type="species:ncbi:9606">human</span>
There is now considerable evidence from studies in vitro with RA synovium and/or co-cultures that IL-17 is a pro-inflammatory cytokine produced only by cells of the immune system, which is thought to contribute to inflammation associated with RA [29]. IL-17 is spontaneously produced by RA synovial membrane cultures, and IL-17-producing cells were found in T cell-rich areas [30] and high levels have been detected in the synovial fluid of patients with RA [21,30,31]. Although bioactive IL-17 is detected in RA and osteoarthritis synovial fluid, the levels of IL-17 were found to be higher in RA synovial fluid than in osteoarthritis synovial fluid [30,31]. The expression of IL-17 in Th1 and Th2 cells seems to be different depending upon the conditions. Th1/Th0, but not Th2, subsets of CD4+ T cell clones isolated from rheumatoid synovium produced IL-17 [32]. In contrast, IL-17 production was found in both Th1 and Th2 clones from human skin-derived nickel-specific T cells [33]. In mice, IL-17 is produced by T cells expressing TNF-alpha but not by Th1 or Th2 cells [19]. IL-17 stimulates transcriptional NF-kappaB activity and IL-6 and IL-8 secretion in fibroblastic, endothelial, and epithelial cells, and induces T cell proliferation [1,5]. Furthermore, it triggers human synoviocytes to produce granulocyte/macrophage colony-stimulating factor and prostaglandin E2 [1], suggesting that IL-17 could be an upstream mediator in the pathogenesis of arthritis and might have a function in fine-tuning the inflammatory response.
###end p 12
###begin p 13
###xml 102 111 98 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 112 114 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 178 187 174 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 251 253 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 254 256 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 484 486 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 609 611 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 908 910 892 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1090 1091 1074 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 71 76 <span type="species:ncbi:9606">human</span>
T cell IL-17 also stimulates the production of IL-1 and TNF-alpha from human PBMC-derived macrophages in vitro [34]. It enhances IL-1-mediated IL-6 production by RA synoviocytes in vitro as well as TNF-alpha-induced synthesis of IL-1, IL-6, and IL-8 [35,36]. This indicates that IL-17 synergizes with IL-1 and TNF, and it has been shown that the combination of TNF-alpha blockade with IL-1 and IL-17 blockade is more effective for controlling IL-6 production in RA synovium cultures [37]. In addition, IL-17 induces RANKL expression, which is an essential cytokine for osteoclastogenesis and bone resorption [31]. IL-17 can synergize with these cytokines (IL-1, TNF, and RANKL), but probably acts directly as well. Furthermore, when IL-17 is combined with other cytokines that are already thought to be important in arthritic disease (such as TNF-alpha and IL-1), even more marked tissue destruction occurs [37] (Lubberts E, Koenders MI, Van den Berg WB, unpublished data). These observations strongly implicate IL-17 as having an important function in the disease pathogenesis of RA (Fig. 1).
###end p 13
###begin title 14
Role of IL-17 in T cell immunity and/or propagation of joint inflammation
###end title 14
###begin p 15
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 747 749 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 960 962 960 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1181 1183 1181 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1308 1310 1308 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1670 1672 1670 1672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1673 1675 1673 1675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 140 144 <span type="species:ncbi:10090">mice</span>
###xml 454 458 <span type="species:ncbi:10090">mice</span>
###xml 645 649 <span type="species:ncbi:10090">mice</span>
###xml 790 798 <span type="species:ncbi:9606">patients</span>
###xml 1578 1584 <span type="species:ncbi:10090">murine</span>
In arthritis, IL-17 is a pro-inflammatory cytokine thought to contribute to the joint inflammatory process [38]. Studies in IL-17-deficient mice revealed that IL-17 has an important function in the activation of T cells in allergen-specific T cell-mediated immune responses [28]. Furthermore, IL-17 has a function in the antigen-specific T cell activation phase of CIA [39]. Of interest, CIA was markedly but not completely suppressed in IL-17-deficient mice. IL-17 was responsible for the priming of collagen-specific T cells and for collagen-specific IgG2a production [39]. In contrast, the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist could be completely prevented after inactivation of IL-17 [40]. In line with the situation in most RA patients, low systemic levels of IL-17 were found after the immunization protocol of CIA but IL-17 expression in the synovium gradually increased after the onset of CIA [41]. Early neutralization of endogenous IL-17 using the IL-17 receptor IgG1 Fc fusion protein starting after the immunization protocol during the initial phase of arthritis suppresses the onset of experimental arthritis [41]. Moreover, neutralizing endogenous IL-17 with anti-IL-17 sera after the onset of CIA still diminished the severity of CIA [42]. Histological analysis confirmed the suppression of joint inflammation, and systemic IL-6 levels were significantly decreased after treatment with anti-IL-17 antisera. In contrast, systemic as well as local IL-17 overexpression using an adenoviral vector expressing murine IL-17 accelerated the onset of CIA and aggravated synovial inflammation at the site [41,43]. These observations strongly implicate a role for IL-17 at various levels in disease pathogenesis of arthritis. IL-17 seems to have a function in T cell immunity and in the propagation of joint inflammation.
###end p 15
###begin title 16
Role of IL-17 in cartilage destruction
###end title 16
###begin p 17
###xml 170 171 170 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 203 212 203 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 409 418 409 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 433 434 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 123 127 <span type="species:ncbi:10090">mice</span>
###xml 531 537 <span type="species:ncbi:9913">bovine</span>
IL-17 has dual effects on cartilage. This T cell cytokine inhibits chondrocyte metabolism in intact articular cartilage of mice and induces proteoglycan breakdown (Table 2) [44-47]. Furthermore, studies in vitro showed the induction of metalloproteinases by IL-17 in synoviocytes and chondrocytes [48-50]. Interestingly, the IL-17 family subtypes IL-17F and IL-17E also showed cartilage destructive potential in vitro [11,47] (Table 2). Another IL-17 family member, IL-17B, has been shown to be expressed by chondrocytes in normal bovine articular cartilage, mostly in the mid and deep zones [18].
###end p 17
###begin p 18
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 118 126 118 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 500 509 500 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 613 615 613 615 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 698 700 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 701 703 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 819 821 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1006 1008 1003 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1201 1210 1190 1199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1211 1213 1200 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 1226 1234 1215 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 514 517 <span type="species:ncbi:9823">pig</span>
IL-17 shares biological activities with IL-1, which is a key cytokine in the induction of cartilage destruction [51]. In vitro, IL-17 suppresses matrix synthesis by articular chondrocytes through enhancement of nitric oxide production [45,52-54]. However, it has been shown that the effects of IL-17 on matrix degradation and synthesis were not dependent on IL-1 production by chondrocytes and IL-1Ra did not block IL-17-induced matrix release nor did they prevent the inhibition of matrix synthesis in vitro with pig articular cartilage explants [47]. In contrast, the IL-17-induced production of prostaglandin E2 and nitric oxide by cartilage explants is dependent on leukemia inhibitory factor [47,54]. Interestingly, an IL-1-independent role of IL-17 in the pathogenesis of experimental arthritis was demonstrated [41]. The downstream signaling pathways for IL-17 and IL-1 seem to be distinct, and differential activation of activator protein 1 (AP-1) members by IL-17 and IL-1beta has been described [49]. Although IL-1 is by far the more catabolic cytokine in experimental arthritis in comparison with TNF-alpha, the combination of IL-17 and TNF-alpha synergizes to induce cartilage destruction in vitro [55] as well as in vivo (Lubberts E, unpublished data). These data suggest that IL-17 alone or in combination with TNF-alpha might circumvent the catabolic effects of IL-1 on cartilage.
###end p 18
###begin title 19
Interrelation between IL-17, polymorphonuclear cell influx, and cartilage destruction
###end title 19
###begin p 20
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 505 506 505 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 627 628 627 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 3 7 <span type="species:ncbi:10090">mice</span>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 269 273 <span type="species:ncbi:10090">mice</span>
###xml 411 415 <span type="species:ncbi:10090">mice</span>
###xml 583 587 <span type="species:ncbi:10090">mice</span>
In mice, local overexpression of IL-17 in the knee joint of both naive mice and mice immunized with type II collagen (CII) leads to enhanced influx of polymorphonuclear cells (PMNs) [41]. A main difference between IL-17 over-expression in naive and CII-immunized DBA-1 mice was the observation that, in CIA, PMNs were heavily sticking to patella and femur cartilage, a phenomenon that was not observed in naive mice. Interestingly, under both conditions, local IL-17 induced proteoglycan depletion (Table 2). However, no chondrocyte death and cartilage erosion was observed in naive mice after local IL-17 gene transfer (Table 2). In contrast, local IL-17 aggravates cartilage erosion in CIA [41].
###end p 20
###begin p 21
###xml 202 206 <span type="species:ncbi:10090">mice</span>
The lack of irreversible cartilage destruction under naive conditions in contrast to CIA conditions might be due to the lack of immune complexes formed during IL-17-induced joint inflammation in normal mice. Although IL-17 overexpression induced enhanced synovial stromelysin (pro-matrix metalloproteinase [pro-MMP]-3) expression under naive as well as CIA conditions (Lubberts E, unpublished data), the presence of immune complexes might be required for the cleavage process of pro-MMPs into active MMPs. This phenomenon is not well understood.
###end p 21
###begin p 22
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
The elevated neutrophil influx and subsequent sticking to anti-CII immune complexes in the cartilage surface layer during CIA probably releases oxygen species and proteolytic enzymes present in PMNs directly into the surface of cartilage, thereby escaping inhibitors present in the synovial fluid [41,56,57]. IL-17 might enhance immune complex formation in CIA because IL-17 has a crucial function in activating autoantigen-specific cellular and humoral immune responses [39].
###end p 22
###begin p 23
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 510 512 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 608 612 <span type="species:ncbi:10090">mice</span>
In contrast to aggravation of cartilage damage by IL-17 overexpression, neutralizing endogenous IL-17 in arthritis models protects against cartilage destruction. Both reversible proteoglycan depletion and the irreversible cartilage markers chondrocyte death and cartilage surface erosion were suppressed after neutralizing IL-17 after the onset of CIA [42]. A reduced influx of PMNs was noted and fewer IL-1beta-positive cells were detected in the synovial infiltrate after treatment with anti-IL-17 antibody [42]. Furthermore, the induction of chronic relapsing streptococcal cell wall-induced arthritis in mice deficient in the IL-17 receptor (IL-17R) revealed the critical role for T cell IL-17/IL-17R signaling in driving synovial IL-1 expression and different metalloproteinases (Koenders MI, Kolls JK, Van den Berg WB, Lubberts E, unpublished data). These observations suggest that the presence of T cell IL-17 in the synovial infiltrate has major influences on PMN influx, synovial IL-1 expression, and the cartilage destructive process. IL-17 therefore seems to be a significant target for the treatment of cartilage destruction in T cell-mediated arthritis.
###end p 23
###begin title 24
Role of IL-17 in bone erosion
###end title 24
###begin p 25
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 385 394 381 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 395 397 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 479 481 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 536 538 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 607 609 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 766 768 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 990 992 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 1159 1161 1151 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1162 1164 1154 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 1549 1551 1541 1543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1552 1554 1544 1546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 1671 1673 1663 1665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 1298 1302 <span type="species:ncbi:10090">mice</span>
###xml 1466 1470 <span type="species:ncbi:10090">mice</span>
###xml 1793 1797 <span type="species:ncbi:10090">mice</span>
In addition to the role of IL-17 in cartilage destruction, this T cell cytokine is a potent stimulator of osteoclastogenesis (Fig. 2). Promotion of type I collagen degradation in synovium and bone by IL-17 has been demonstrated, and when combined with IL-1, a marked synergistic release of collagen was noted [44]. IL-17 in combination with TNF-alpha increased osteoclastic resorption in vitro [58]. Furthermore, IL-17 induced the expression of RANKL in cultures of osteoblasts [31]. RANKL is a crucial regulator of osteoclastogenesis [59]. RANKL binds to its unique receptor activator of NF-kappaB (RANK) [60], and the RANKL/ RANK pathway seems of crucial importance in osteoclastogenesis and the bone erosion process. RANKL and the decoy receptor osteoprotegerin [61] are important positive and negative regulators of osteoclastogenesis and bone resorption. Regulation of IL-17 and RANKL, as shown by IL-4 gene therapy in collagen arthritis, prevents osteoclastogenesis and bone erosion [62]. Systemic treatment with a soluble IL-17 receptor fusion protein (sIL-17R:Fc) starting before arthritis expression in experimental arthritis prevented bone erosion [41,63]. Moreover, development of bone erosion in the chronic relapsing streptococcal cell wall-induced arthritis model in IL-17R-deficient mice was significantly suppressed (Lubberts E, Van den Berg WB, Kolls JK, unpublished data). In contrast, local IL-17 overexpression in the knee joint of CII-immunized mice resulted in promotion of collagen arthritis and aggravated joint destruction [43,64]. In the CIA model it was shown that IL-17 promoted bone erosion through loss of the RANKL/osteoprotegerin balance [64]. Systemic treatment with osteoprotegerin prevented joint damage induced by local IL-17 gene transfer in CII-immunized mice. This strongly suggests that IL-17 is a potent inducer of RANKL and that the IL-17-induced promotion of bone erosion is strongly mediated by RANKL.
###end p 25
###begin title 26
Interrelation between IL-17 and IL-1/TNF
###end title 26
###begin p 27
###xml 135 137 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 323 325 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 485 487 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 560 569 547 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 639 641 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 642 644 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 801 810 784 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 840 842 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 31 36 <span type="species:ncbi:10090">mouse</span>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 479 483 <span type="species:ncbi:10090">mice</span>
###xml 658 662 <span type="species:ncbi:10090">mice</span>
Overexpression of IL-17 in the mouse knee joint of CII-immunized mice resulted in elevated levels of IL-1beta protein in the synovium [41]. Intriguingly, blocking of IL-1alpha/beta with neutralizing antibodies had no effect on the IL-17-induced synovial inflammation and joint damage, implying an IL-1-independent pathway [41]. This direct potency of IL-17 was underscored in the unabated IL-17-induced exaggeration of bacterial cell wall-induced arthritis in IL-1beta-deficient mice [41]. Apart from IL-1, synergistic effects between IL-17 and TNF in systems in vitro have been reported regarding cytokine induction and cartilage damage [44,55]. Because in mice IL-17-producing T cells also express TNF-alpha we performed blocking studies with IL-17 and TNF inhibitors. In line with the observations in vitro with RA synovial co-cultures [37], a combination blockade of TNF-alpha and IL-17 suppressed continuing CIA and was more effective than neutralizing TNF alone (Lubberts E, Van den Berg WB, unpublished data). It is of interest that TNF-alpha-dependent arthritis can be circumvented by IL-17 (Koenders MI, Lubberts E, Van den Berg WB, unpublished data). This underscores the potential of IL-17 to act additively or even synergistically with IL-1/TNF. Moreover, it also shows that T cell IL-17 can replace the proinflammatory/catabolic function of IL-1/ TNF, directly or through interplay with other macrophage-driven factors.
###end p 27
###begin title 28
Role of IL-17 in other inflammatory/autoimmune diseases
###end title 28
###begin p 29
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 351 352 351 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 353 354 353 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 558 560 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 685 687 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 735 737 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 902 904 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 1084 1086 1084 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1326 1328 1326 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 1575 1577 1575 1577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 1700 1702 1700 1702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 1703 1705 1703 1705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
###xml 1825 1827 1825 1827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B78">78</xref>
###xml 1871 1873 1871 1873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
###xml 934 938 <span type="species:ncbi:10090">mice</span>
###xml 1216 1220 <span type="species:ncbi:10090">mice</span>
###xml 1469 1484 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1837 1845 <span type="species:ncbi:9606">patients</span>
Apart from the role of IL-17 in autoimmune arthritis, IL-17 and its family members exhibit a potential role in other inflammatory diseases, such as lung, gut, and skin inflammation [65-69]. IL-17 has a function in T-cell-triggered inflammation by stimulating stromal cells to secrete various cytokines and growth factors associated with inflammation [1,2]. IL-17 regulates gene expression and protein synthesis of the complement system [70]. It has a regulatory role on C3 expression and synthesis and an amplifying effect on TNF-induced factor B synthesis [70]. In addition, IL-17 stimulates granulopoiesis and is a strong inducer of neutrophil recruitment through chemokine release [65,71]. Furthermore, IL-17 promotes angiogenesis [72] and a role for IL-17 was suggested in allogeneic T cell proliferation that might be mediated in part through a maturation-inducing effect on dendritic cells (DC) [73]. Studies in IL-17-deficient mice revealed that this T cell cytokine had an important function in the activation of T cells in allergen-specific T cell-mediated immune responses [28]. IL-17 induced neutrophil accumulation in infected lungs. Greatly diminished recruitment of neutrophils into lungs was found in mice with homozygous deletion of the IL-17 receptor in response to a challenge with a Gram-negative pathogen [74]. Overproduction of IL-17 has been associated with several chronic disease conditions, suggesting a role of IL-17 in these diseases. IL-17E transgenic mice showed growth retardation, jaundice, a Th2-biased response, and multi-organ inflammation [75]. Furthermore, IL-17 expression was observed in ovarian, endometrial, and cervical cancers exhibiting angiogenic effects [76,77]. Elevated levels of IL-17 were found in other autoimmune diseases, such as experimental autoimmune encephalomyelitis [78], and in patients with systemic sclerosis [79]. However, further studies are needed to unravel the role of IL-17 in the pathogenesis of these autoimmune inflammations.
###end p 29
###begin title 30
Conclusions
###end title 30
###begin p 31
###xml 96 97 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 103 105 103 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
IL-17 is a T cell-derived cytokine produced by activated T cells, predominantly by activated CD4+CD45RO+ memory cells, and is expressed in the synovium of patients with RA. IL-17 has a function in T cell-triggered inflammation by stimulating different cell types to secrete various cytokines and chemokines. In addition, IL-17 shows additive or even synergistic effects with IL-1 and TNF in inducing cytokine expression and joint pathology. Furthermore, T cell IL-17 is a potent inducer of RANKL, a crucial cytokine in osteoclastogenesis and bone resorption. IL-17 can act together with these cytokines but has direct pathological effects as well. It has been shown that IL-17 has IL-1-independent activities in inducing synovial inflammation and joint destruction in experimental arthritis. Furthermore, IL-17 has a function in prolongation of the arthritis process and can be considered an important target for the treatment of destructive arthritis.
###end p 31
###begin p 32
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
The discovery of IL-17 family members may further extend the role of this cytokine family in arthritis pathology. IL-17F showed similar biological effects to those of IL-17; however, IL-17F is expressed in activated monocytes in addition to activated T cells. Further studies will be required to determine the contribution and precise mechanism of action of the novel IL-17 family member(s), with emphasis on the interaction with other known key cytokines in the pathogenesis of arthritis. Furthermore, IL-23 seems to be an important physiological stimulus for the induction of IL-17 and IL-17F, although other mediators might also be involved [21,23,26,27].
###end p 32
###begin p 33
###xml 294 301 <span type="species:ncbi:9606">patient</span>
Results so far suggest strongly that IL-17 is a novel target for the treatment of destructive arthritis. Because it is known that this T cell factor can have synergistic effects with catabolic/inflammatory mediators, it is tempting to speculate that IL-17 levels can influence whether or not a patient will respond to anti-TNF and anti-IL-1 therapy. Anti-IL-17 cytokine therapy might be an interesting new anti-rheumatic approach that could contribute to the prevention of joint destruction as an adjunct to anti-TNF and anti-IL-1 therapy.
###end p 33
###begin title 34
Abbreviations
###end title 34
###begin p 35
CIA = collagen-induced arthritis; CII = type II collagen; IL = interleukin; MMP = matrix metalloproteinase; PMN = polymorphonuclear cell; RA = rheumatoid arthritis; RANKL = receptor activator of NF-kappaB ligand; TNF = tumor necrosis factor.
###end p 35
###begin title 36
Competing interests
###end title 36
###begin p 37
The author(s) declare that they have no competing interests.
###end p 37
###begin title 38
Acknowledgements
###end title 38
###begin p 39
This work was supported by a Veni Fellowship of the Netherlands Organization for Scientific Research (NWO) grant 906-02-038 (E Lubberts) and a Dutch Arthritis Association Grant NR 00-1-302.
###end p 39
###begin article-title 40
T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines
###end article-title 40
###begin article-title 41
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human IL-17: a novel cytokine derived from T cells
###end article-title 41
###begin article-title 42
###xml 65 66 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 69 70 62 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 73 75 66 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse IL-17: a cytokine preferentially expressed by alphabeta TCR+CD4-CD8- T cells
###end article-title 42
###begin article-title 43
CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a Herpesvirus Saimiri gene
###end article-title 43
###begin article-title 44
Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor
###end article-title 44
###begin article-title 45
IL-17: prototype member of an emerging cytokine family
###end article-title 45
###begin article-title 46
Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family
###end article-title 46
###begin article-title 47
A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity
###end article-title 47
###begin article-title 48
IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1
###end article-title 48
###begin article-title 49
Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production
###end article-title 49
###begin article-title 50
IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding
###end article-title 50
###begin article-title 51
Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin-17 signal transduction
###end article-title 51
###begin article-title 52
NF-kappaB-inducing kinase is a common mediator of IL-17-, TNF-alpha, and IL-1beta-induced chemokine promoter activation in intestinal epithelial cells
###end article-title 52
###begin article-title 53
Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB
###end article-title 53
###begin article-title 54
###xml 34 39 <span type="species:ncbi:9606">human</span>
IL-17-induced cytokine release in human bronchial epithelial cells in vitro: role of mitogen-activated protein (MAP) kinases
###end article-title 54
###begin article-title 55
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Expression, modulation and signaling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis
###end article-title 55
###begin article-title 56
Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer
###end article-title 56
###begin article-title 57
Interleukin-17 family and IL-17 receptors
###end article-title 57
###begin article-title 58
Microbial lipopeptides induce the production of IL-17 in Th cells
###end article-title 58
###begin article-title 59
###xml 21 26 <span type="species:ncbi:9606">human</span>
Cell-cell contact of human T cells with fibroblasts changes lymphocytic mRNA expression: increased mRNA expression of interleukin-17 and interleukin-17 receptor
###end article-title 59
###begin article-title 60
###xml 45 53 <span type="species:ncbi:9606">patients</span>
High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism
###end article-title 60
###begin article-title 61
IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger
###end article-title 61
###begin article-title 62
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17
###end article-title 62
###begin article-title 63
###xml 89 111 89 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Klebsiella pneumoniae </italic>
###xml 89 110 <span type="species:ncbi:573">Klebsiella pneumoniae</span>
Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection
###end article-title 63
###begin article-title 64
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain
###end article-title 64
###begin article-title 65
Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation
###end article-title 65
###begin article-title 66
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice
###end article-title 66
###begin article-title 67
###xml 69 73 <span type="species:ncbi:10090">mice</span>
Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses
###end article-title 67
###begin article-title 68
Interleukin-17 in rheumatoid arthritis. If T cells were to contribute to inflammation and destruction through synergy
###end article-title 68
###begin article-title 69
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium
###end article-title 69
###begin article-title 70
###xml 30 38 <span type="species:ncbi:9606">patients</span>
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
###end article-title 70
###begin article-title 71
IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells
###end article-title 71
###begin article-title 72
###xml 131 136 <span type="species:ncbi:9606">human</span>
Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma and interleukin-4 induced activation of human keratinocytes
###end article-title 72
###begin article-title 73
###xml 103 108 <span type="species:ncbi:9606">human</span>
IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1beta and TNFalpha, by human macrophages
###end article-title 73
###begin article-title 74
Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines
###end article-title 74
###begin article-title 75
Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukin 1, 6, and 8 in skin and synovial fibroblasts: a possible role as a 'fine-tuning cytokine' in inflammation processes
###end article-title 75
###begin article-title 76
The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model
###end article-title 76
###begin article-title 77
The role of IL-17 and family members in the pathogenesis of arthritis
###end article-title 77
###begin article-title 78
###xml 81 85 <span type="species:ncbi:10090">mice</span>
Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice
###end article-title 78
###begin article-title 79
###xml 112 116 <span type="species:ncbi:10090">mice</span>
IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist
###end article-title 79
###begin article-title 80
IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis
###end article-title 80
###begin article-title 81
###xml 35 41 <span type="species:ncbi:10090">murine</span>
Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion
###end article-title 81
###begin article-title 82
###xml 72 76 <span type="species:ncbi:10090">mice</span>
Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction
###end article-title 82
###begin article-title 83
IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis
###end article-title 83
###begin article-title 84
###xml 95 101 <span type="species:ncbi:10090">murine</span>
Reduction of interleukin-17-induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin-4
###end article-title 84
###begin article-title 85
###xml 56 62 <span type="species:ncbi:10090">murine</span>
Effect of interleukin-17 on proteoglycan degradation in murine knee joints
###end article-title 85
###begin article-title 86
Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo
###end article-title 86
###begin article-title 87
Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis
###end article-title 87
###begin article-title 88
###xml 59 64 <span type="species:ncbi:9606">human</span>
Interleukin 17 (IL-17) induces collagenase-3 production in human osteoclastic chondrocytes via AP-1 dependent activation: differential activation of AP-1 members by IL-17 and IL-1beta
###end article-title 88
###begin article-title 89
Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines
###end article-title 89
###begin article-title 90
Anti-cytokine therapy in chronic destructive arthritis
###end article-title 90
###begin article-title 91
###xml 59 64 <span type="species:ncbi:9606">human</span>
Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage
###end article-title 91
###begin article-title 92
###xml 127 132 <span type="species:ncbi:9606">human</span>
Mitogen-activated protein kinase and nuclear factor kappaB together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes: possible role of transactivating factor mitogen-activated protein kinase-activated protein kinase (MAPKAPK)
###end article-title 92
###begin article-title 93
###xml 123 125 123 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 151 156 <span type="species:ncbi:9606">human</span>
Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci
###end article-title 93
###begin article-title 94
Interleukin 17 synergizes with tumour necrosis factor alpha to induce cartilage destruction in vitro
###end article-title 94
###begin article-title 95
Elastase secreted by activated polymorphonuclear leukocytes causes chondrocyte damage and matrix degradation in intact articular cartilage: escape from inactivation by alpha-1-proteinase inhibitor
###end article-title 95
###begin article-title 96
###xml 28 33 <span type="species:ncbi:9606">human</span>
Elastase and cathepsin G of human monocytes: quantification of cellular content, release in response to stimuli, and heterogeneity in elastase-mediated proteolytic activity
###end article-title 96
###begin article-title 97
Interleukin-17: a new bone acting cytokine in vitro
###end article-title 97
###begin article-title 98
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
###end article-title 98
###begin article-title 99
RANK is essential for ostoclast and lymph node development
###end article-title 99
###begin article-title 100
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density
###end article-title 100
###begin article-title 101
IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion
###end article-title 101
###begin article-title 102
###xml 52 55 <span type="species:ncbi:10116">rat</span>
Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein
###end article-title 102
###begin article-title 103
###xml 31 37 <span type="species:ncbi:10090">murine</span>
IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the RANKL/OPG balance
###end article-title 103
###begin article-title 104
###xml 26 31 <span type="species:ncbi:9606">human</span>
Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways
###end article-title 104
###begin article-title 105
New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25
###end article-title 105
###begin article-title 106
Increased expression of interleukin 17 in inflammatory bowel disease
###end article-title 106
###begin article-title 107
Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukin 1, 6, and 8 in skin and synovial fibroblasts: a possible role as a 'fine-tuning cytokine' in inflammation processes
###end article-title 107
###begin article-title 108
Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions
###end article-title 108
###begin article-title 109
IL-17 regulates gene expression and protein synthesis of the complement system, C3 and factor B, in skin fibroblasts
###end article-title 109
###begin article-title 110
###xml 35 39 <span type="species:ncbi:10090">mice</span>
IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines
###end article-title 110
###begin article-title 111
Interleukin-17 promotes angiogenesis and tumor growth
###end article-title 111
###begin article-title 112
Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors
###end article-title 112
###begin article-title 113
Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defence
###end article-title 113
###begin article-title 114
###xml 21 27 <span type="species:ncbi:10090">murine</span>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
Forced expression of murine IL-17E induces growth retardation, jaundice, a Th2-biased response, and multiorgan inflammation in mice
###end article-title 114
###begin article-title 115
Expression of IL-17 mRNA in ovarian cancer
###end article-title 115
###begin article-title 116
###xml 70 75 <span type="species:ncbi:9606">human</span>
###xml 95 104 <span type="species:ncbi:10090">nude mice</span>
Interleukin-17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice
###end article-title 116
###begin article-title 117
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis
###end article-title 117
###begin article-title 118
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Increased interleukin-17 production in patients with systemic sclerosis
###end article-title 118
###begin article-title 119
Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis
###end article-title 119
###begin title 120
Figures and Tables
###end title 120
###begin p 121
Schematic overview of interleukin-17 (IL-17) in relation to other key cytokines in the pathogenesis of arthritis. RANKL, receptor activator of NF-kappaB ligand; TNF, tumor necrosis factor.
###end p 121
###begin p 122
Schematic overview of the mechanism of interleukin-17 (IL-17) in bone resorption. The interrelationship of IL-17 with receptor activator of NF-kappaB ligand (RANKL), IL-1, tumor necrosis factor (TNF) and the modulatory role of IL-4 and osteoprotegerin (OPG) is presented. OC, osteoclast.
###end p 122
###begin p 123
Interleukin (IL)-17 family members and their receptors
###end p 123
###begin p 124
Effects of interleukin (IL)-17 on chondrocyte metabolism and cartilage destruction
###end p 124
###begin p 125
CIA, collagen-induced arthritis; MMP, matrix metalloproteinase; NO, nitric oxide; SCW, streptococcal cell wall-induced arthritis.
###end p 125

